Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 16/20 | 0.62 |
| ▸ | SIRT1 | Q96EB6 | 13/20 | 0.62 |
| ▸ | SIRT3 | Q9NTG7 | 10/20 | 0.58 |
| ▸ | CTSL | P07711 | 1/20 | 0.58 |
| ▸ | CTSS | P25774 | 1/20 | 0.58 |
| ▸ | CPB1 | P15086 | 1/20 | 0.55 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.55 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6361021 | 1.00 | SIRT2 (0.62) | SIRT2SIRT1SIRT3CTSLCTSS | |
| SCHEMBL6360713 | 0.87 | SMN1; SMN2 (0.56) | SIRT2SIRT1SIRT3CTSLCTSS | |
| SCHEMBL6365264 | 0.85 | CTSS (0.53) | SIRT2SIRT1CTSLCTSS | |
| SCHEMBL6358735 | 0.85 | CTSK (0.69) | CTSLCTSS | |
| SCHEMBL8750916 | 0.85 | CTSL (0.62) | SIRT2SIRT1CTSLCTSS | |
| SCHEMBL16782306 | 0.83 | SIRT2 (0.66) | SIRT2SIRT1SIRT3CPB1CPB2 | |
| SCHEMBL6361536 | 0.82 | SIRT5 (0.57) | SIRT2SIRT1SIRT3CTSLCTSS | |
| SCHEMBL6361539 | 0.82 | SIRT5 (0.57) | SIRT2SIRT1SIRT3CTSLCTSS | |
| SCHEMBL11737428 | 0.82 | CTSL (0.76) | SIRT2SIRT1SIRT3CTSLCTSS | |
| SCHEMBL8192271 | 0.80 | CAPN1 (0.53) | SIRT2SIRT1SIRT3CTSLCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6858591-B2 | Antibiotic AA 896 analogs | WYETH HOLDINGS CORPORATION (US) | 2005-02-22 | — | — | US | disclosed |
| US-20030087874-A1 | 2-amino-3-hydroxy-3-uridyl-propanoic acid ester derivatives | AMERICAN CYANAMID COMPANY | 2003-05-08 | — | — | US | disclosed |
| WO-2002086139-A1 | ANTIBIOTIC AA 896 ANALOGS | WYETH HOLDINGS CORPORATION (US) | 2002-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087874-A1 | 2-amino-3-hydroxy-3-uridyl-propanoic acid ester derivatives | UMPS, METTL3, FPR3 | SIRT2 3523/4885SIRT1 3835/4885SIRT3 3214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.